INTRODUCTION

Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of death with 1,276,106 new cases and 358,989 deaths worldwide in 2018 alone.\textsuperscript{1} At some point during their lives, an estimated 12.1% of men will be diagnosed with prostate cancer. In 2017, 3,170,339 men were living with prostate cancer in the United States.\textsuperscript{1,2}

1,276,106 new cases and 358,989 deaths worldwide in 2018 alone.\textsuperscript{1} At some point during their lives, an estimated 12.1% of men will be diagnosed with prostate cancer. In 2017, 3,170,339 men were living with prostate cancer in the United States.\textsuperscript{1,2}
States. On presentation, 76% are localized or confined to the prostate, 13% have spread to regional lymph nodes, 6% have metastasized, and 5% are unknown or unstaged.\textsuperscript{2} This distribution is significant in which survival rates widely vary depending on stage with 5-year relative survival rates for localized, regional, and metastatic prostate cancer being approximately 100%, 100%, and 31%, respectively.\textsuperscript{3}

In men diagnosed with metastatic disease, androgen deprivation therapy (ADT) is the initial standard of care.\textsuperscript{4} However, prostate cancer cells eventually become resistant to ADT and castration-resistant prostate cancer (CRPC) emerges. In men with CRPC, broadly available treatment options are chemotherapy, immunotherapy, and second-line androgen deprivation therapy (SAT).\textsuperscript{5} In 2004, the USFDA approved docetaxel, the first agent shown to improve survival rates in patients with CRPC.\textsuperscript{6} Since then, several drugs shown to improve survival rates have been approved including cabazitaxel and sipuleucel-T in 2010 and second-line androgen therapies (SAT) abiraterone and enzalutamide in 2011 and 2012, respectively.\textsuperscript{7} More recently, additional SAT agents, apalutamide and darolutamide, as well as the PARP inhibitor olaparib have been added to the armamentarium against CRPC.\textsuperscript{8–10}

Despite the approval of docetaxel in 2004, Wu and colleagues reported that overall and prostate cancer-specific survival did not improve in patients with metastatic disease in the docetaxel era (years 2004–2009).\textsuperscript{11} However, given the recent advent of several blockbuster drugs in the SAT class for CRPC since 2010 combined with the implementation of more intense therapy supported by clinical trials,\textsuperscript{12,13} we hypothesized that there would be significant improvements in survival among patients diagnosed with metastatic prostate cancer from the pre-docetaxel to SAT era (years 2000–2016).

2 | MATERIALS AND METHODS

2.1 | Data Sources

The study sample was composed of patients at least 18 years old with distant prostate cancer from the Surveillance, Epidemiology, and End Results (SEER) Program, which publishes epidemiologic data on the incidence and survival rates of cancer in the United States. Using SEER\textsuperscript{*}Stat statistical software, patient information was extracted from the Incidence – SEER 18 Regs Research Data, Nov 2018 Sub (2000–2016), which collects information on patients from Connecticut, Detroit, Atlanta, San Francisco/Oakland, Hawaii, Iowa, New Mexico, Seattle-Puget Sound, and Utah, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding San Francisco/San Jose-Monterey/Los Angeles, Kentucky, Louisiana, New Jersey, and George excluding Atlanta/Rural Georgia. Information on chemotherapy and radiation treatment for these patients was extracted from Incidence – SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (2000–2016).

2.2 | Study variables

This study primarily examined the following study variables: age, race/ethnicity, year of diagnosis, treatment with prostatectomy and/or radiotherapy or no local therapy, and metastatic subclass. Metastatic subclass was based on the American Joint Committee on Cancer (AJCC) Stage 5\textsuperscript{rd} edition for patients diagnosed in 2000–2003, adjusted AJCC 6\textsuperscript{th} edition for those in 2004–2015, and derived SEER Combined Stage M for those in 2016.

2.3 | Statistical analysis

The primary study outcomes were overall survival (OS) and prostate cancer-specific survival (PCSS) based on the diagnostic time period and metastatic subclass when available. Secondary study outcomes investigated changes across years in the distribution of age, race/ethnicity, and treatment with prostatectomy and/or radiotherapy or no local therapy.

The following three time periods were examined: January 2000–December 2003 (era 1), January 2004–December 2009 (era 2), and January 2010–December 2016 (era 3). Overall and prostate cancer-specific survival were estimated using the Kaplan–Meier product limit method stratified by three time periods and their differences were analyzed using the log-rank test and univariate and multivariable Cox proportional hazards models were applied to assess the risk of death and prostate cancer-specific death with time periods. Hazard ratios (HR) and 95% confidence intervals were reported. In multivariable model, age, treatment, and race/ethnicity were analyzed. Because stage is not available for era 1, the stage was adjusted in comparing eras 2 and 3. Changes in the distribution of age, race/ethnicity, and treatment across time periods were analyzed using Pearson’s chi-square test. All statistical analyses were performed using Stata/SE 15.0 with a p-value of less than or equal to 0.05 considered statistically significant.

3 | RESULTS

3.1 | Overall survival of patients with metastatic prostate cancer shows modest improvements between 2000 and 2016

The study sample consisted of 41,149 patients at least 18 years old diagnosed with distant prostate cancer
between 2000 and 2016. We excluded 392 patients from era 1 (years 2000–2003), 159 from era 2 (years 2004–2009), and 192 from era 3 (years 2010–2016) for being M0 due to the likelihood of stage misattribution. Median follow-up for era 1, 2, and 3 for OS was 179, 117, and 36 months, respectively.

Patient characteristics among the three eras are shown in Table 1. Among the variables examined, men in the most recent SAT era (era 3, 2010–2016) were younger with a median age of 71 versus 73 and 72 in era 1 and era 2, respectively (p < 0.001). The racial/ethnic distribution of patients with metastatic prostate cancer also changed with the number of non-Hispanic white and black patients decreasing from 64.59% in 2000–2003 to 63.13% in 2010–2016 and 19.89% to 17.87%, respectively, and the number of Hispanic, non-Hispanic Asian/Pacific Islander, and non-Hispanic American Indians/Alaskan Natives increasing from 9.63% to 11.91%, 5.22% to 5.78%, and 0.43% to 0.60% during that same time period, respectively (p < 0.001). In addition, a stage migration was observed between eras 2 and 3 with a significant shift from M1c to M1b and M1a (p < 0.001). Breakdown of metastatic stage and serum prostate-specific antigen levels was not available for era 1. Notably, there was no significant change in the utilization of local treatment (p = 0.376).

The differences in OS across the three time periods were statistically significant. Median OS was 24 months in both eras 1 and 2, while OS increased by 4 months to 28 months in era 3 (p < 0.0001). Kaplan–Meier curve for 3-year OS is shown in Figure 1 (p < 0.0001, log-rank test). Using era 1 as the referent in Cox proportional hazard model (Table 2), era 2 was not associated with OS in both the unadjusted (HR 0.9858, 95% CI 0.9519–1.0209, p = 0.4233) and adjusted analysis (HR 1.0078, 95% CI 0.9731–1.0437, p = 0.6650). In contrast, era 3 was associated with improved OS unadjusted (HR 0.8795, 95% CI 0.8499–0.9102, p < 0.0001) and adjusted (HR 0.9182, 95% CI 0.8871–0.9503, p < 0.0001). In the adjusted analysis, we accounted for age, local therapy, and race/ethnicity. Additional factors correlating with OS were Hispanic ethnicity (adjusted HR 0.9496, 95% CI 0.9089–0.9921, p = 0.0207), Asian race (adjusted HR 0.7406, 95% CI 0.6957–0.7884, p < 0.0001), and receipt of local therapy (adjusted HR 0.3741, 95% CI

### Table 1: Characteristics of patients with metastatic prostate cancer

|                          | Era 1, 2000–2003 | Era 2, 2004–2009 | Era 3, 2010–2016 | p-value |
|--------------------------|-----------------|-----------------|-----------------|---------|
| Sample size              | 8,066           | 13,039          | 20,044          |         |
| Median age (years) (range)| 73 (19–99)     | 72 (28–99)      | 71 (18–99)      | <0.001  |
| Median follow-up (months) (range) | 179 (177–180) | 117 (115–118)  | 36 (35–36)      |         |
| Median overall survival (months) | 24 (23–25)     | 24 (24–25)      | 28 (27–28)      | <0.001  |
| Median cause-specific survival (months) | 24 (23–24)     | 24 (24–25)      | 28 (27–28)      | <0.001  |
| Race/ethnicity            |                 |                 |                 | <0.001  |
| Non-Hispanic White        | 5,210 (64.59%)  | 8,356 (64.08%)  | 12,653 (63.13%) |         |
| Non-Hispanic Black        | 1,604 (19.89%)  | 2,366 (18.15%)  | 3,582 (17.87%)  |         |
| Hispanic                  | 777 (9.63%)     | 1,448 (11.11%)  | 2,388 (11.91%)  |         |
| Non-Hispanic Asian/PI     | 421 (5.22%)     | 756 (5.80%)     | 1,159 (5.78%)   |         |
| Non-Hispanic American Indian/Alaska Native | 35 (0.43%)    | 78 (0.60%)     | 142 (0.71%)     |         |
| Non-Hispanic Unknown Race | 19 (0.24%)      | 35 (0.27%)      | 120 (0.60%)     |         |
| Stage                     |                 |                 |                 | <0.001  |
| Blank(s) or N/A           | 6 (0.07%)       | 29 (0.22%)      | 95 (0.47%)      |         |
| M1NOS                     | -               | 488 (3.74%)     | 1,125 (5.61%)   | <0.001  |
| M1                        | 8,059 (99.91%)  | 12,492 (95.80%) | 18,819 (93.89%) |         |
| M1a                       | -               | 627 (5.02%)     | 1,165 (6.19%)   |         |
| M1b                       | -               | 8,537 (68.34%)  | 14,078 (74.81%) |         |
| M1c                       | -               | 3,328 (26.64%)  | 3,576 (19.00%)  |         |
| MX                        | 1 (0.01%)       | 30 (0.23%)      | 5 (0.02%)       |         |
| Local Treatment           |                 |                 |                 | 0.376   |
| Prostatectomy and/or Radiotherapy | 170 (2.11%)  | 313 (2.40%)    | 466 (2.32%)     |         |
| No local therapy          | 7,896 (97.89%)  | 12,726 (97.60%) | 19,578 (97.68%) |         |
0.3277–0.4272, p < 0.0001). In contrast, non-Hispanic Black race and age older than 70 were associated with a significantly shorter OS (adjusted HR 1.0651, 95% CI 1.0288–1.1027, p = 0.0004 and adjusted HR 1.6193, 95% CI 1.5303–1.7135, p < 0.0001, respectively).

3.2 | Prostate cancer-specific survival (PCSS) of patients with metastatic prostate cancer also shows modest improvements between 2000 and 2016

As with OS, differences in cause-specific survivals across the three time periods also were statistically significant (Table 1). The Kaplan–Meier curve for 3-year PCSS is shown in Figure 2 (p < 0.0001, log-rank test). The Cox proportional hazard model demonstrated that PCSS also did not change from era 1 to era 2 (Table 3, adjusted HR 1.0042, 95% CI 0.9694–1.0402, p = 0.8169) but did improve in era 3 (adjusted HR 0.9088, 95% CI 0.8778–0.9408, p < 0.0001). Again, adjusted variables were age, local treatment, and race/ethnicity. Additional factors associated with improved PCSS were Hispanic ethnicity (adjusted HR 0.9330, 95% CI 0.8920–0.9758, p = 0.0025), Asian race (adjusted HR 0.7364, 95% CI 0.6909–0.7850, p < 0.0001), and receipt of local treatment (adjusted HR 0.3751, 95% CI 0.3284–0.4285, p < 0.0001). Non-Hispanic Black race and age older than 70 were again associated with shorter PCSS (adjusted HR 1.0652, 95% CI 1.0287–1.1029, p = 0.0004 and adjusted HR 1.6180, 95% CI 1.5284–1.7127, p < 0.0001, respectively).

3.3 | Improvement in survival limited to M1b and M1c patients

While the stage is not provided in era 1, the data were available for 12492 and 18819 men in era 2 and 3, respectively (Table 4). When 3-year OS was stratified by stage between era 2 and 3, we found that patients with M1a prostate cancer did not benefit (Figure 3, p = 0.4051, log-rank test). However, men with M1b and M1c demonstrated improvements in 3-year OS (Figure 3, p < 0.0001 and p = 0.0017, respectively, log-rank test). Patients with M1b prostate cancer saw an increase in median OS from 26 months in era 2 to 29 months in era 3, while those with M1c prostate cancer had a more modest increase in median OS from 18 to 20 months across the same time periods (Table 5). Similarly, 3-year PCSS did not improve between the two eras for men with M1a prostate cancer (Figure 4, p = 0.3465, log-rank test). As for M1b and M1c patients, increase in 3-year PCSS was again seen in 2010–2016 (Figure 4, p < 0.0001 and p = 0.0005, log-rank test, respectively). Between 2004–2009 and 2010–2016, median PCSS increased for men with M1b disease from 26 to 29 months (Table 5).

Using respective era 2 outcomes as referents, Cox proportional hazards model demonstrated that unadjusted and adjusted OS increased from era 2 to era 3 in men with M1b and M1c diagnosis (adjusted HR 0.9309, 95% CI 0.8973–0.9657, p < 0.0001 and adjusted HR 0.9306 95% CI 0.8759–0.9886, p = 0.0197, respectively) (Table 6). Likewise, concerning PCSS, only those with M1b and M1c prostate cancer demonstrated an increased survival from...
2004–2009 to 2010–2016 (adjusted HR 0.9263, 95% CI 0.8927–0.9612, \( p < 0.0001 \) and adjusted HR 0.9217, 95% CI 0.8671–0.9797, \( p = 0.0088 \), respectively) (Table 6).

**4 | DISCUSSION**

In the present study, we have investigated survival in the SAT era in men diagnosed with metastatic prostate cancer using the SEER database. Our study corroborated the findings of a previous report that found no improvements in OS and PCSS in patients with metastatic prostate cancer between 2000–2003 and 2004–2009 despite the approval of docetaxel in 2004.\(^{11}\) We did find, however, a modest but statistically significant increase in OS and PCSS of 4 months, between 2004–2009 and 2010–2016. A previous study found a similar increase in PCSS but slightly lower improvement in OS of 3 months between 2004–2008 and 2009–2014,\(^{14}\) which when taken with our observations, suggest further improvement in survival in 2015–2016. Overall, our observations suggest that there has been only a marginal improvement in treating metastatic prostate cancer in the modern SAT era.

Although the first agent shown to be effective in treating metastatic CRPC was docetaxel in 2004,\(^{6}\) no survival change was noted in this study until the 2010–2016 era. These findings suggest that the approval of additional drugs since 2010 may have contributed to an improved survival not found between 2000–2003 and 2004–2009. For example, first approved in 2010, cabazitaxel was shown to improve the median survival from 12.7 months in patients given the standard mitoxantrone to 15.1 months in patients given cabazitaxel.\(^{15}\) More importantly, treatment with cabazitaxel plus prednisone improved overall survival in patients whose disease had progressed during or after docetaxel-based therapy. Likewise, additional

| TABLE 2 Cox proportional hazards analysis of factors associated with overall survival |
|--------------------------------------|------------------------|-----------------|-----------------|------------------------|
| Sample size (%) | HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value |
| Sample Size | 41,149 |
| Era |
| 1 (2000–2003) | 8,066 (19.60%) | 1 (Referent) | 1 (Referent) |
| 2 (2004–2009) | 13,039 (31.69%) | 0.9858146 (0.9519384–1.020896) | 0.4233 | 1.007765 (0.9730918–1.043673) | 0.6650 |
| 3 (2010–2016) | 20,044 (48.71%) | 0.8795156 (0.8498592–0.9102069) | <0.0001 | 0.918208 (0.8871394–0.9503646) | <0.0001 |
| Age |
| <55 | 2,817 (6.85%) | 1 (Referent) | 1 (Referent) |
| 55–70 | 16,162 (39.28%) | 0.9918329 (0.935859–1.051155) | 0.7820 | 0.9987666 (0.9423184–1.058596) | 0.9668 |
| >70 | 22,170 (53.88%) | 1.639387 (1.55011–1.733806) | <0.0001 | 1.619348 (1.530347–1.713525) | <0.0001 |
| Race/Ethnicity |
| Non-Hispanic White | 26,219 (63.72%) | 1 (Referent) |
| Non-Hispanic Black | 7,552 (18.35%) | 0.9801204 (0.9471046–1.014287) | 0.2507 | 1.065119 (1.028826–1.102693) | 0.0004 |
| Hispanic | 4,613 (11.21%) | 0.9011678 (0.8246194–0.9721516) | <0.0001 | 0.9495967 (0.9089019–0.9921135) | 0.0207 |
| Non-Hispanic Asian/PI | 2,336 (5.68%) | 0.7530729 (0.7074133–0.8016795) | <0.0001 | 0.7405733 (0.6956624–0.7883835) | <0.0001 |
| Non-Hispanic American Indian/Alaska Native | 255 (0.62%) | 1.024736 (0.8701149–1.206832) | 0.7697 | 1.056592 (0.8971218–1.244408) | 0.5096 |
| Non-Hispanic Unknown Race | 174 (0.42%) | 0.2887188 (0.2029708–0.4106922) | <0.0001 | 0.3077151 (0.2163109–0.4377431) | <0.0001 |
| Treatment |
| No local therapy | 40,200 (97.69%) | 1 (Referent) |
| Prostatectomy and/or Radiotherapy | 949 (2.31%) | 0.3235701 (0.2834962–0.3693087) | <0.0001 | 0.3741484 (0.3277183–0.4271566) | <0.0001 |
therapies introduced since 2010 such as sipuleucel-T, abiraterone, and enzalutamide were shown to increase median survival by 4.1, 3.9, and 4.8 months, respectively, in men with metastatic CRPC.\textsuperscript{16-19} Our finding that median OS increased by 4 months from 2004–2009 to 2010–2016 corroborates the results of the aforementioned clinical trials.

It should be noted that there are alternative explanations for our observation concerning the recent improvement in survival among men diagnosed with metastatic prostate cancer. For example, it is entirely possible that the increased survival in the modern era for M1 prostate cancer patients may be due to increased acceptance and utilization of docetaxel since its approval in 2004. In its phase 3 study, TAX 327, the median survival for patients with metastatic prostate cancer improved from 16.5 months in the mitoxantrone group to 18.9 months in patients given docetaxel every 3 weeks and 17.4 months in patients given weekly docetaxel.\textsuperscript{6} However, given the relatively rapid progression of M1 disease, such delayed benefit of docetaxel is unlikely. A more probable explanation is that docetaxel may not have been embraced readily by treating physicians and patients. Indeed, a recent study has suggested that nearly half of men diagnosed with metastatic prostate cancer are not treated or treated with androgen deprivation therapy only.\textsuperscript{20}

Despite numerous advances in treatment including second-line anti-androgens (abiraterone and enzalutamide) between 2010 and 2016, it is noteworthy that median OS improved by mere 4 months. Given that such gain is over two decades, the magnitude of the improvement in outcomes is surprisingly small. This finding may be explained in part by previous studies, which report shared resistance between drugs such as abiraterone and enzalutamide. Possible mechanisms include the presence of androgen-receptor splice variant 7 messenger RNA (AR-V7) and induction of glucocorticoid receptor expression.\textsuperscript{21,22} Another study found that patients receiving abiraterone before docetaxel were less likely to respond to docetaxel and achieve a PSA response than patients who had not received abiraterone, suggesting cross-resistance between the two drugs.\textsuperscript{23} Collectively, these published data suggest that the effect of these drugs in prolonging OS and PCSS among patients with metastatic prostate cancer is not additive. In this regard, more intense initial therapies have been endorsed recently,\textsuperscript{12,13} and new second-line anti-androgens and PARP inhibitors are now available.\textsuperscript{8-10} As such, analysis in 3–5 years is necessary to assess whether these newer agents are additive or have overlapping resistance mechanisms with the current standard of care. Additionally, previous studies have reported that the U.S. Preventive Services Task Force’s recommendation against PSA screening in 2012 may have contributed to a 25% increase in the rate of newly diagnosed metastatic prostate cancer from 2004 to 2014.\textsuperscript{24} This increase may have worsened some patients’ staging at presentation and further curtailed the survival improvement in mPCa during the SAT era. Notwithstanding, more investigations should be focused on identifying and targeting novel pathways that are outside the conventional androgen signaling pathways to make a major improvement in outcomes in men with metastatic prostate cancer.

When factors associated with improved survival were assessed, local therapy status was associated with the best outcome (adjusted HR 0.3741, 95% CI 0.3277–0.4272, \( p < 0.0001 \)). This observation is consistent with previous
reports that confirmed the association between local therapy (surgery or radiation) and longer survival. More recently, subgroup analyses of prospective studies suggested the benefit of local radiotherapy in men with a low volume metastatic prostate cancer. Currently, large-scale prospective studies such as SIMCAP (NCT03456843) and SWOG 1802 (NCT03678025) are underway to further assess the role of surgery and/or radiation in men who present with M1 prostate cancer.

Notably, among racial/ethnic groups, Non-Hispanic Black patients with metastatic prostate cancer had decreased OS and PCSS compared to Non-Hispanic White patients (adjusted HR 1.0651, 95% CI 1.0288–1.1027, \( p = 0.0004 \) and adjusted HR 1.0652, 95% CI 1.0287–1.1029, \( p = 0.0004 \), respectively). Given the recent finding that the survival disparity between White and Black patients was no longer observed after the U.S. Preventive Services Task Force recommended against PSA screening in May 2012, the current observation suggests that there may be different rates of treatment among Black patients relative to White patients with M1 prostate cancer. Indeed, it has been shown that after adjusting for risk factors such as age, PSA, and sites of metastases, Black patients with metastatic castration-resistant prostate cancer who were treated in phase III clinical trials with docetaxel and prednisone (DP) or treatments including DP actually reported increased overall survival relative to White patients. These observations collectively suggest that fewer Black patients with metastatic prostate cancer may be receiving effective treatment regimens compared to White patients. Further analysis is underway to test this hypothesis.

Further stratification of the data by M stage found that the median OS and PCSS increased only in patients with M1b or M1c prostate cancer. Such observation may be a statistical artifact as the sample size of M1a was relatively small (627 in era 2 and 1165 in era 3). Alternatively,
potential explanations include a different treatment approach based on stage. For example, the use of SAT may be higher in men with high metastatic burden. However, given that men with prostate cancer die from widely metastatic disease, patients with M1a will likely be treated with the newer agents at some point during disease progression. A more provocative hypothesis is that the biology of M1a prostate cancer may be fundamentally different from that of M1b and M1c diseases. Given that the tumor microenvironment plays a critical role in tumor biology,31,32

| TABLE 4 | Characteristics of patients with metastatic prostate cancer by stage |
|----------------|------------------|------------------|------------------|
|               | n (%), 2004–2009 | n (%), 2010–2016 | p-value         |
| M1a            |                  |                  |                 |
| Sample size    | 627              | 1,165            |                 |
| Median age (years) | 69 (40–97)       | 68 (40–95)       | 0.104           |
| Race/ethnicity |                  |                  | 0.399           |
| Non-Hispanic White | 422 (67.30%)    | 733 (62.92%)     |                 |
| Non-Hispanic Black | 107 (17.07%)    | 208 (17.85%)     |                 |
| Hispanic       | 70 (11.16%)      | 150 (12.88%)     |                 |
| Non-Hispanic Asian/PI | 21 (3.35%)     | 53 (4.55%)       |                 |
| Non-Hispanic American Indian/Alaska Native | 4 (0.64%)     | 10 (0.86%)       |                 |
| Non-Hispanic Unknown Race | 3 (0.48%)     | 11 (0.94%)       |                 |
| Local treatment|                  |                  | 0.351           |
| RP and/or XRT  | 31 (4.94%)       | 70 (6.01%)       |                 |
| No local therapy| 596 (95.06%)   | 1,095 (93.99%)   |                 |
| M1b            |                  |                  |                 |
| Sample size    | 8,537            | 14,078           | < 0.001         |
| Median age (years) | 72 (35–99)       | 71 (34–99)       | 0.011           |
| Race/ethnicity |                  |                  |                 |
| Non-Hispanic White | 5,483 (64.23%)  | 9,013 (64.02%)   |                 |
| Non-Hispanic Black | 1,517 (17.77%)  | 2,438 (17.32%)   |                 |
| Hispanic       | 939 (11.00%)     | 1,627 (11.56%)   |                 |
| Non-Hispanic Asian/PI | 524 (6.14%)  | 818 (5.81%)      |                 |
| Non-Hispanic American Indian/Alaska Native | 50 (0.59%)     | 99 (0.70%)       |                 |
| Non-Hispanic Unknown Race | 24 (0.28%)   | 83 (0.59%)       |                 |
| Local treatment|                  |                  | 0.370           |
| RP and/or XRT  | 203 (2.38%)      | 309 (2.19%)      |                 |
| No local therapy| 8,334 (97.62%) | 13,769 (97.81%) |                 |
| M1c            |                  |                  |                 |
| Sample size    | 3,328            | 3,576            | < 0.001         |
| Median age (years) | 72 (29–99)       | 70 (39–99)       | 0.088           |
| Race/ethnicity |                  |                  |                 |
| Non-Hispanic White | 2,095 (62.95%)  | 2,139 (59.82%)   |                 |
| Non-Hispanic Black | 640 (19.23%)    | 718 (20.08%)     |                 |
| Hispanic       | 380 (11.42%)     | 465 (13.00%)     |                 |
| Non-Hispanic Asian/PI | 187 (5.62%)  | 216 (6.04%)      |                 |
| Non-Hispanic American Indian/Alaska Native | 19 (0.57%)     | 24 (0.67%)       |                 |
| Non-Hispanic Unknown Race | 7 (0.21%)     | 14 (0.39%)       |                 |
| Local treatment|                  |                  | 0.222           |
| RP and/or XRT  | 66 (1.98%)       | 57 (1.59%)       |                 |
| No local therapy| 3,262 (98.02%) | 3,519 (98.41%)   |                 |
a more detailed analysis of additional databases combined with basic laboratory studies is necessary to test this concept.

The strength of our current investigation is that the real-world data with a very large sample size have been analyzed. While previous studies have examined survival improvements in OS and PCSS of mPCA patients over the last few decades, none have conducted survival analyses stratified by M stage and reported a survival benefit limited to patients with bone and visceral metastasis to our knowledge. Notwithstanding, the limitation is that the study is inherently retrospective. Another limitation is that we do not know what if any second-line treatments these men received. Indeed, many men in this cohort may not have access to these typically expensive medications. Finally, the
adoption of new treatments cannot be performed using SEER only. As such, our study should be considered a hypothesis-generating study.

5 | CONCLUSIONS

Since 2000–2003, there has been a modest improvement in survival in patients who are diagnosed with metastatic prostate cancer, with increases in median OS and PCSS of 4 months, respectively. Interestingly, the benefit in survival outcome was observed only in M1b and M1c prostate cancer patients.

ACKNOWLEDGMENTS

We thank the National Cancer Institute for the use of their Surveillance, Epidemiology, and End Results Program (SEER) database.
CONFLICT OF INTEREST
All authors have no significant conflict of interest with the content of this study.

ETHICS STATEMENT
This study did not require the approval of an Institutional Review Board (IRB), because the Surveillance, Epidemiology, and End Results Program (SEER) database is a publicly available, de-identified database.

DATA AVAILABILITY STATEMENT
This study used data from the Surveillance, Epidemiology, and End Results Program (SEER) database, which is publicly available at https://seer.cancer.gov/data/.

ORCID
Isaac Yi Kim https://orcid.org/0000-0001-7167-8853

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Surveillance E. & End Results Program. Cancer Stat Facts: Prostate Cancer. Bethesda, MD: National Cancer Institute; 2017.
3. Society AC. Survival Rates for Prostate Cancer. 2020.
4. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Society AC. Survival Rates for Prostate Cancer. 2020.
5. Virgo KS, Basch E, Loblaw DA, et al. Second-line hormonal therapy for men with chemotherapy-naive, castration-resistant prostate cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2017;35:1952-1964.
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
7. Shore ND. Embarrassment of riches: therapies that improve overall survival in mCRPC. Everyday Urol - Oncol Insights. 2016:1.
8. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408-1418.
9. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in non-metastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246.
10. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
11. Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818-823.
12. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163-1177.
13. Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737-746.
14. Bandini M, Pompe RS, Marchioni M, et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. Int Urol Nephrol. 2018;50:71-78.
15. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
16. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
17. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
18. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
19. Virgo KS, Rumble RB, Singer EA. Second-line hormonal therapy for men with chemotherapy-naive castration-resistant prostate cancer: american society of clinical oncology provisional clinical opinion summary. J Oncol Pract. 2017;13:459-461.
20. Ke X, Lafeuille M-H, Romdhani H, et al. Treatment patterns in men with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US). J Clin Oncol. 2020;38(15_suppl):e19131.
21. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028-1038.
22. Arora V, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to androgen receptors by bypassing androgen receptor blockade. Cell. 2013;155:1309-1322.
23. Schweizer MT, Zhou XC, Wang H, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;66:646-652.
24. Bandini M, Mazzone E, Preisser F, et al. Increase in the annual rate of newly diagnosed metastatic prostate cancer: a contemporory analysis of the surveillance, epidemiology and end results database. Eur Urol Oncol. 2018;1:314-320.
25. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65:1058-1066.
26. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353-2366.
27. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410-418.
28. Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic
prostate cancer: what the individual trials are hoping to answer. *BJU Int.* 2020;125:792-800.

29. Kim IE, Jang TL, Kim S, et al. Abrogation of survival disparity between black and white individuals after the USPSTF’s 2012 prostate-specific antigen-based prostate cancer screening recommendation. *Cancer.* 2020;126:5114-5123.

30. Halabi S, Dutta S, Tangen CM, et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. *J Clin Oncol.* 2019;37:403-410.

31. Baghban R, Roshangar L, Jahanban-Esfahlan R, et al. Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Commun Signal.* 2020;18:59.

32. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. *Cancer Res.* 2019;79:4557-4566.

**How to cite this article:** Kim IE, Jang TL, Kim S, et al. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. *Cancer Med.* 2021;10:7909–7920. [https://doi.org/10.1002/cam4.4074](https://doi.org/10.1002/cam4.4074)